Skip to main content

Posts

Showing posts with the label uk

Lindsay Dudfield, Executive Director and CEO of Jindalee Resources Limited, Executed MOU with POSCO Holdings For Joint Research At McDermitt Lithium Project

JINDALEE RESOURCES LIMITED  (ASX: JRL) (Jindalee, the Company) is an Australian exploration company with Tier 1 lithium deposits in its portfolio in the United States. The Company’s core goals are to discover world-class mineral deposits and generate shareholder wealth. The United States is one of the largest marketplaces for lithium demand, and Jindalee is a leading company committed to help meet future demand. The Company is focussing efforts into developing its McDermitt lithium deposit. Jindalee Resources was listed on the Australian Securities Exchange (ASX) on 11th July 2002 and raised AUD 2.70 million. Now, it is a pure-play United States lithium company. Jindalee’s Projects: In June 2018, the Company acquired McDermitt and Clayton North, two lithium sediment projects in the United States. Both projects are 100% owned by HiTech Minerals Inc., a wholly owned, US-based subsidiary of Jindalee. Several factors attracted the Company’s interest in these projects including: Potenti...

QX Resources Limited and Steve Promnitz: Supplying high-end demand of battery minerals

QX Resources Limited Projects PILBARA LITHIUM PROJECTS The group’s lithium strategy is centred around hard rock lithium projects in Western Australia’s prolific Pilbara province, where it holds four key projects spanning a total area of  335 KM2  in strategic proximity to some of Australia’s largest lithium deposits. The Pilbara Lithium projects consist of the following: Turner River project : The Turner River project is located in a prime address, 15km south of the Wodgina Project, held by Mineral Resources, one of the largest hard rock lithium deposits globally. The 100% owned 84 km2 area contains a series of high-priority lithium targets with high-grade rock chip assays of 1.6% Li2O, 1.1% Li2O and 4.9% Li2O. Recent drilling indicates significant areas of lithium-bearing pegmatites and lithium-rich micas (lepidolite). Drilling targets the potential for either lithium mica and spodumene-bearing pegmatites or a new large tonnage hard rock lithium deposit near the top of a lith...

Roquefort Therapeutics and CEO Ajan Reginald: An Inspiring Story

Roquefort Therapeutic’s Portfolio The company’s portfolio includes four best-in-class programs, Midkine antibodies, Midkine RNA therapeutics, STAT-6 siRNA and MK cell therapy, built through the acquisition of Lyramid in 2020 and Oncogeni in 2022: Roquefort has two Midkine programs, developed and run by the acquired Lyramid team. Midkine, a heparin-binding protein, has long been known to be important in embryonic development. While barely detectable in healthy adults, Midkine is highly expressed during oncogenesis. MDK hinders the normal immune response to tumours and promotes metastatic spread to other organs, thereby contributing to various levels of cancer progression and reduced patient survival. Roquefort believes its know-how and patent strategy (the combination of the exclusive license and the efforts to patent in-house R&D) have established the entry barrier in targeting MDK. The patent strategy is focused on both the composition of matter patents and method patents for anti...